NFKB1 and breast carcinoma: Subsequent biological assays confirmed that lead compounds 3a and 5b effectively inhibited NF–κBp65 phosphorylation in MCF–7 cells, presenting a promising chemical entity targeting NF–κB in breast cancer cells.